Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lab21 CE marks syphilis test

This article was originally published in Clinica

Executive Summary

Lab21 subsidiary Newmarket Laboratories has CE marked for sale in Europe its early-detection syphilis test. The assay, which can be performed in as little as two hours, detects the first immunoglobulin produced after infection - IgM. The company's previous test detected IgG, which is produced at a later stage of the disease. The test could also prove useful in differential diagnosis of syphilis pathology, said the Cambridge, UK firm. The test is now available throughout Europe.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT049459

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel